Skip Ribbon Commands
Skip to main content
Assoc Prof Lim Wan Teck Darren

Assoc Prof Lim Wan Teck Darren

MBBS (S’pore), MRCP (UK), FAMS

Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology, Medical Oncology

Sub-specialties: Head & Neck, Thoracic-Oncology, Chest (Thoracic-Oncology), Lung, Nasopharynx

Conditions Treated by this Doctor:
Head and Neck Cancer, Larynx Cancer, Lung Cancer, Nasopharyngeal Cancer (Nose Cancer), Oral Cancer, Salivary Gland Cancer, Thyroid Cancer.

Clinical Appointments

  • Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Associate Professor


A/Prof Darren Lim is a Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore. His research interests are in nasopharyngeal, lung, thyroid, and head and neck squamous cancers with focus on clinical trials and biological correlates.


  • MBBS 
  • MRCP (UK) 

Professional Appointments and Committee Memberships

  • Senior Consultant, Department of Medical Oncology, National Cancer Centre Singapore 
  • Director, Investigational Medicine Unit, SingHealth 
  • Associate Professor, Office of Clinical Sciences, Duke-NUS Medical School
  • Director of Research, Department of Medical Oncology, National Cancer Centre Singapore 
  • International Association for the Study of Lung Cancer, Member 
  • American Society of Clinical Oncology, Member 
  • Singapore Society of Oncology, Member 
  • Academy of Medicine Singapore, Fellow


  • 2017 Ministry of Health National Clinician Scientist Award
  • 2012 Ministry of Health National Clinician Scientist Award
  • 2004 Ministry of Health Manpower Development Award

Research Interests

  • Nasopharyngeal cancer
  • Lung cancer
  • Head and Neck cancer


  • Rajasekaran T, Ng QS, Tan DS, Lim WT, Ang MK, Toh CK, Chowbay B, Kanesvaran R, Tan EH. Metronomic chemotherapy: A relook at its basis and rationale. Cancer Lett. 2017 Mar 1;388:328-333. doi: 10.1016/j.canlet.2016.12.013. Epub 2016 Dec 18. 
  • Sutiman N, Tan SW, Tan EH, Lim WT, Kanesvaran R, Ng QS, Jain A, Ang MK, Tan WL, Toh CK, Chowbay B. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. J Thorac Oncol. 2017 Mar;12(3):529-538. doi: 10.1016/j.jtho.2016.11.2225. Epub 2016 Nov 28. 
  • Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. J Clin Oncol. 2017 Jan 10;35(2):157-165. Epub 2016 Nov 21. 
  • Yeo T, Tan SJ, Lim CL, Lau DP, Chua YW, Krisna SS, Iyer G, Tan GS, Lim TK, Tan DS, Lim WT, Lim CT. Sci Rep. 2016 Feb 29;6:22076. doi: 10.1038/srep22076. Microfluidic enrichment for the single cell analysis of circulating tumor cells. 
  • Zhang WC, Chin TM, Yang H, Nga ME, Lunny DP, Lim EK, Sun LL, Pang YH, Leow YN, Malusay SR, Lim PX, Lee JZ, Tan BJ, Shyh-Chang N, Lim EH, Lim WT, Tan DS, Tan EH, Tai BC, Soo RA, Tam WL, Lim B. Nat Commun. 2016 Jun 21;7:11702. doi: 10.1038/ncomms11702. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. 
  • Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, Tan EH, Zhai W, Hillmer AM, Tam WL, Tan DS. Lancet Oncol. 2016 Aug;17(8):e347-62. doi: 10.1016/S1470-2045(16)30123-1. Review. Novel therapeutic targets on the horizon for lung cancer. 
  • Tan EH, Tan DS, Li WY, Haaland B, Ang MK, Chau NM, Toh CK, Tan IB, Koh TS, Thng CH, Chowbay B, Hui KM, Lim WT, Ng QS. Lung Cancer. 2015 Jun;88(3):289-96. doi: 10.1016/j.lungcan.2015.04.001. Epub 2015 Apr 13. Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. 
  • Tan DS, Camilleri-Broët S, Tan EH, Alifano M, Lim WT, Bobbio A, Zhang S, Ng QS, Ang MK, Iyer NG, Takano A, Lim KH, Régnard JF, Tan P, Broët P. Int J Cancer. 2014 Sep 1;135(5):1092-100. doi: 10.1002/ijc.28750. Epub 2014 Apr 3. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics. 
  • Ragin C, Obikoya-Malomo M, Kim S, Chen Z, Flores-Obando R, Gibbs D, Koriyama C, Aguayo F, Koshiol J, Caporaso NE, Carpagnano GE, Ciotti M, Dosaka-Akita H, Fukayama M, Goto A, Spandidos DA, Gorgoulis V, Heideman DA, van Boerdonk RA, Hiroshima K, Iwakawa R, Kastrinakis NG, Kinoshita I, Akiba S, Landi MT, Eugene Liu H, Wang JL, Mehra R, Khuri FR, Lim WT, Owonikoko TK, Ramalingam S, Sarchianaki E, Syrjanen K, Tsao MS, Sykes J, Hee SW, Yokota J, Zaravinos A, Taioli E. Carcinogenesis. 2014 Jun;35(6):1267-75. doi: 10.1093/carcin/bgu038. Epub 2014 Feb 12. HPV-associated lung cancers: an international pooled analysis.
  • Khoo BL, Warkiani ME, Tan DS, Bhagat AA, Irwin D, Lau DP, Lim AS, Lim KH, Krisna SS, Lim WT, Yap YS, Lee SC, Soo RA, Han J, Lim CT. PLoS One. 2014 Jul 7;9(7):e99409. doi: 10.1371/journal.pone.0099409. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e111296. Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. 

Research Trials

  • A phase II, open-label, randomized, controlled study of PDR001 in patients with moderately undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment, 2016 
  • A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (Ascend-7), 2015 
  • A phase III, open-label, multicenter, randomized study evaluating the efficacy and safety of MPDL3280A (Anti-PDL1 Antibody) in combination with carboplatin+paclitaxel or MPDL3280A in combination with carboplatin+nab-paclitaxel versus carboplatin+nab-paclitaxel in chemotherapy-naive patients with stage IV squamous non-small cell lung cancer, 2015 
  • A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive- Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy (Dlim), 2015